Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

CSE:RVV - Post Discussion

Revive Therapeutics Ltd > Not to be all conspiracy like but google...
View:
Post by Trippedstocks on Mar 03, 2021 10:19pm

Not to be all conspiracy like but google...

Plain Language Summary of COVID-19 Global Rheumatology Alliances First Provider-Reported Data Analysis | The COVID-19 Global Rheumatology Alliance

The internet has been scrubbed. Anyone Internet savvy enough? It says site can't be reached for me anymore.

Was one of my Bucillamine bookmarks.
Comment by Trippedstocks on Mar 03, 2021 11:10pm
Treatment with b/tsDMARD mono- therapy just prior to COVID-19 diagnosis was significantly associated with a lower odds of hospitalisation compared with no DMARD therapy (OR=0.46, 95%CI 0.22 to 0.93; p=0.03).
Comment by Trippedstocks on Mar 03, 2021 11:18pm
Link? https://ard.bmj.com/content/79/7/859.abstract
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities